ClinicalTrials.gg
RecruitingNCT05590715Updated Nov 17, 2026

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

An observational study in Autism Spectrum Disorder, sponsored by Stalicla SA. Recruiting at 21 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Stalicla SA · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.
Updated Nov 17, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
6th of 114
1,500 · median 132
Started
2022
with 56 others
Observational
114 of 773
23 open now
Primary completion
2027-03
later than 81 of 201 live
Registered
574th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 6th largest by planned enrollment of the 114 observational ones that give a count, is one of 57 that started in 2022, is one of 114 observational ones, reaches primary completion later than 81 of the 201 other live ones, and was the 574th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male or female individuals with an autism diagnosis as defined by the DSM-5, adults (from 18 to 65 years of age, inclusive) and adolescents (from 12 to 17 years of age, inclusive).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants previously diagnosed with ASD ()
  • Available well-documented health records within the first 2 years of life
  • Participants must have a parent or reliable caregiver who agrees to provide information about the participant
  • Participants willing and consenting or assenting to participate.

Exclusion criteria

Exclusion Criteria:

  • Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or illness without fever (as judged by the investigator), within 10 days before any study assessment.
  • If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Clinical characterisation of the ASD-Phen1 and ASD-Phen2 subpopulations.

    A semi-structured medical questionnaire will be administered to collect clinical (sign and symptoms) and anthropomorphic features.

    Time frame: Day 0

  2. Molecular characterization of the ASD-Phen1 and ASD-Phen2 subpopulations

    Better characterize subpopulations of ASD subjects and potentially identify/confirm a molecular signature specific of each subpopulation.

    Time frame: Day 0

07

Study locations

11 of 21 sites recruiting
  • SARRC
    Phoenix, Arizona 85006, United States
    Recruiting
  • California Neuroscience Research
    Sherman Oaks, California 91403, United States
    Recruiting
  • BioPhase Research
    Miami, Florida 33137, United States
    Terminated

    Not enrolling at this site — choose another above.

  • The Angel Medical Research
    Miami Lakes, Florida 33016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
    • Melissa Baer · Contact
    • Caceres Tamar, MD · Principal investigator
  • University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders
    Columbia, Missouri 65211, United States
    Recruiting
    • Nicole Takahashi · Contact
    • David Berversdorf, MD · Principal investigator
  • Golden Hearts Diagnostic
    Alamogordo, New Mexico 88210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Red Oak Psychiatry Associates
    Houston, Texas 77090, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alpine Research Organization
    Clinton, Utah 84015, United States
    Recruiting
    • Amy Kenley · Contact
  • Children's Health Queensland Hospital and Health Service
    South Brisbane, Queensland 4101, Australia
    Not yet recruiting
    • Emily Milburn · Contact
  • Mater Misericordiae Limited
    South Brisbane, Queensland 4101, Australia
    Not yet recruiting
    • Caitlin Bennett · Contact
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
    Not yet recruiting
    • Rupali Saikia · Contact
  • Locuspsych
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
    Not yet recruiting
    • Kylie Crompton · Contact
  • Hospital General Universitario Dr Balmis
    Alicante, 30010, Spain
    Recruiting
    • Maria Auxiliadora Javaloyes Sanchis, MD · Contact
    • Maria Auxiliadora Javaloyes Sanchis, MD · Principal investigator
  • Hospital Clinic of Barcelona
    Barcelona, 8036, Spain
    Recruiting
    • Rosa Calvo Escalona, MD/PhD · Contact
    • Rosa Calvo Escalona, MD/PhD · Principal investigator
  • Hospital Infantil Universitario Nino Jesus (HIUNJS)
    Madrid, 28009, Spain
    Recruiting
    • Silvia Gutierrez Priego, MD · Contact
    • Silvia Gutierrez Priego, MD · Principal investigator
  • Hospital universitario Infanta Leonor
    Madrid, 28031, Spain
    Recruiting
    • Francisco Javier Quintero Gutiérrez del Álamo, MD/PhD · Contact
    • Francisco Javier Quintero Gutiérrez del Álamo, MD/PhD · Principal investigator
  • Hospital Universitario Puerta De Hierro Majadahonda
    Majadahonda, 28222, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Policlina Gipuzkoa
    San Sebastián, 20014, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Álvaro Cunqueiro
    Vigo, 36213, Spain
    Recruiting
    • Jose Manuel Olivares Diez, MD/PhD · Contact
    • Jose Manuel Olivares Diez, MD/PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 21, 2022
StartActual
Oct 13, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: added a•••@stalicla.com. See the current contact
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Contact Study contact changed: added a•••@stalicla.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05590715
Lead sponsor
Stalicla SA
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Oct 13, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Eric Painbeni, PhD
Contact
clinical@stalicla.com
+41 22 545 12 42
Amazon Austin, PhD
Contact
a.austin@stalicla.com
Charlotte Keywood, MD
study director · Stalicla SA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion